Exonhit Enters Into Research Agreement With Pfizer to Identify Alzheimer’s Disease Biomarkers

12-Oct-2011 - France

Exonhit announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform.

As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on AD molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.

Financial details were not disclosed.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance